Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

Virax Biolabs Receives Ethical Approval for its Virax Immune COVID-19 Analytical Performance Study from the SBEBO Foundation for the Assessment of Ethics of Biomedical Research

Virax Biolabs (“Virax” or the “Company”), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, is pleased to announce that it has received ethical approval for its Analytical Performance Study for the Virax Immune COVID-19 Flow Cytometry Kit from the ethics committee of the Stichting Beoordeling Ethiek Biomedisch Onderzoek (“SBEBO”) Foundation for the Assessment of Ethics of Biomedical Research (the “Ethics Committee”).

The Ethics Committee is an independent Medical Research Ethics Committee for biomedical scientific research involving human subjects taking place within the Netherlands.

The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit. Virax Immune is a new In-Vitro Diagnostic (IVD) test seeking detection of T-Cell immune responses to viral threats such as COVID-19 and its variants. Unlike antibodies, T-Cells coordinate the immune system against viral attack. Their detection can give an indication of inherent protection from disease for those yet to be infected and may be useful to determine the degree of long-term protection an individual has after recovering from Covid-19 or other viral threats.

“We are pleased to take this critical step towards kicking off our upcoming Analytical Performance Study for the Virax Immune IVD Testing Device,” commented James Foster, Chief Executive Officer of Virax. “We believe that our immunological diagnostic profiling technique represents cutting-edge technology that will enable us to change the diagnostic approaches of the IVD market with respect to major viral diseases. We look forward to launching the Analytical Performance Study in the coming quarter.”

Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.

Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

spot_img
spot_img

Our Sister Publication

Medical Device News Magazine